Another Pfizer deal: Opko's once-weekly growth hormone

The latest transaction in Pfizer's year-end dealmaking flurry gives the company an exclusive global license for Opko Health's once-weekly human growth hormone (hGH) candidate Lagova (hGH-CTP), which complements the big pharma's once-daily growth hormone Genotropin (somatropin).

The latest transaction in Pfizer's year-end dealmaking flurry gives the company an exclusive global license for Opko Health's once-weekly human growth hormone (hGH) candidate Lagova (hGH-CTP), which complements the big pharma's once-daily growth hormone Genotropin (somatropin).

Opko acquired Lagova in 2013 when it bought Prolor for about $480m in stock (scripintelligence.com, 24 April 2013). Miami,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category